Metabolomics Workbench : NIH Data Repository

MB Sample ID: SA021794

Local Sample ID:	sample30
Subject ID:	SU000454
Subject Type:	Human
Subject Species:	Homo sapiens
Taxonomy ID:	9606
Species Group:	Human

Select appropriate tab below to view additional metadata details:

Treatment:

Treatment ID:	TR000468
Treatment Summary:	All individuals were enrolled in the Mayo Clinic Alzheimer's Disease Research Center (ADRC) and donated their brain to the Neuropathology Core. Eligibility criteria for the proposed study included an autopsy report and available blood at the last study visit before death. Standardized methods for sampling and neuropathologic examination were performed according to the third report of the DLB consortium (CDLB) [20], [21] and the Consortium to Establish a Registry for Alzheimer's Disease guidelines [22]. Braak neurofibrillary tangle (NFT) stage was determined based on the distribution of NFTs assessed with Bielschowsky silver stain [23]. A consensus clinical diagnosis was determined at each study visit by a panel of neurologists, neuropsychologists, and nurses who reviewed all patient information including neuropsychological results, activities of daily living, and the Clinical Dementia Rating scale. The diagnosis of dementia was based on DSM-III-R criteria [24]. We identified the following four groups: (1) Cognitively normal-normal pathology [CN, n = 21]. These individuals had no LBs, had low-likelihood AD according to the National Institute of Aging (NIA)-Reagan Criteria [25], and were cognitively normal as of their last study visit. (2) High-likelihood DLB [n = 13]. These individuals met criteria for high-likelihood DLB according to the CDLB, had Braak NFT stage ≤ IV, low to intermediate-likelihood AD, and a diagnosis of dementia as of the last study visit. Twelve patients had diffuse LB and one had transitional LB. (3) Intermediate-likelihood DLB (n = 17). These individuals had both DLB and AD pathologies. They had transitional (n = 14) or diffuse (n = 3) LBs, met criteria for intermediate-likelihood DLB according to the CDLB, had Braak NFT stage ≥ IV, intermediate to high-likelihood AD, and a diagnosis of dementia as of the last study visit. (4) Alzheimer's disease pathology (AD, n = 18). These individuals had high (n = 16) or intermediate (n = 2) likelihood AD according to NIA-Reagan criteria, had Braak NFT stage ≥ IV, no LBs, and had a diagnosis of probable AD dementia. Given our previous report that plasma ceramides increase with age and are higher in women [26], we frequency matched the four groups by sex and also by age.

Treatment ID:

TR000468

Treatment Summary:

All individuals were enrolled in the Mayo Clinic Alzheimer's Disease Research Center (ADRC) and donated their brain to the Neuropathology Core. Eligibility criteria for the proposed study included an autopsy report and available blood at the last study visit before death. Standardized methods for sampling and neuropathologic examination were performed according to the third report of the DLB consortium (CDLB) [20], [21] and the Consortium to Establish a Registry for Alzheimer's Disease guidelines [22]. Braak neurofibrillary tangle (NFT) stage was determined based on the distribution of NFTs assessed with Bielschowsky silver stain [23]. A consensus clinical diagnosis was determined at each study visit by a panel of neurologists, neuropsychologists, and nurses who reviewed all patient information including neuropsychological results, activities of daily living, and the Clinical Dementia Rating scale. The diagnosis of dementia was based on DSM-III-R criteria [24]. We identified the following four groups: (1) Cognitively normal-normal pathology [CN, n = 21]. These individuals had no LBs, had low-likelihood AD according to the National Institute of Aging (NIA)-Reagan Criteria [25], and were cognitively normal as of their last study visit. (2) High-likelihood DLB [n = 13]. These individuals met criteria for high-likelihood DLB according to the CDLB, had Braak NFT stage ≤ IV, low to intermediate-likelihood AD, and a diagnosis of dementia as of the last study visit. Twelve patients had diffuse LB and one had transitional LB. (3) Intermediate-likelihood DLB (n = 17). These individuals had both DLB and AD pathologies. They had transitional (n = 14) or diffuse (n = 3) LBs, met criteria for intermediate-likelihood DLB according to the CDLB, had Braak NFT stage ≥ IV, intermediate to high-likelihood AD, and a diagnosis of dementia as of the last study visit. (4) Alzheimer's disease pathology (AD, n = 18). These individuals had high (n = 16) or intermediate (n = 2) likelihood AD according to NIA-Reagan criteria, had Braak NFT stage ≥ IV, no LBs, and had a diagnosis of probable AD dementia. Given our previous report that plasma ceramides increase with age and are higher in women [26], we frequency matched the four groups by sex and also by age.